Denis Riendeau

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K

Jacques Yves Gauthier, Nathalie Chauret, Wanda Cromlish et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 473 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts

Stacia Kargman, S. Charleson, Mark E. Cartwright et al. · Gastroenterology · 1996 · 465 citations · Full text

Life Sciences, Biochemistry, Pharmacology +12

Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2

Denis Riendeau, M. David Percival, Christine Brideau et al. · Journal of Pharmacology and Experimental Therapeutics · 2001 · 460 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor

Petpiboon Prasit, Z Wang, Christine Brideau et al. · Bioorganic & Medicinal Chemistry Letters · 1999 · 429 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +9

L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-<i>t</i>-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor

John W. Gillard, A W Ford‐Hutchinson, Chi-Chung Chan et al. · Canadian Journal of Physiology and Pharmacology · 1989 · 328 citations

Medicine, Biochemistry, Pharmacology +14